

Exploring Solutions to Improve Equity in Medication Use Quality

Thursday, May 11 | 3:30-4:45 p.m. CT



Justin Bioc
Devoted Health



Rina Shah Walgreens



Christie Teigland Inovalon



Courtney Walker Novo Nordisk



Sharon Jhawar SCAN Health Plan Moderator







Understanding the

CMS Health Equity Index

- Health Equity Index (Part C & D) developed as an enhancement to Medicare Advantage
- Goal is to incentivize contracts to perform well for socially atrisk beneficiaries
- Summarizes contract performance across a subset of Star measures
- A contract will need to be measured on at least half the measures to receive an index value
- The measures will use 2 years of data
- Contracts with 500 or more members will be eligible and only measures with 30 or more members will be included
- Initial stratifications will include disability and dual eligible/low-income subsidy status
 - Other stratifications added over time (e.g., race/ethnicity, income, education)
- Will be included as part of MA 5 STAR rating system by 2027 (impacting the plan's overall STAR rating and reward factor)

Are You Prepared? Get Ahead of the Curve

Health Equity Index (HEI): 14 Claims Based Measures

Breast Cancer Screening	Diabetes Care –Blood Sugar Controlled
Colorectal Cancer Screening	Rheumatoid Arthritis Management
Annual Flu Vaccine	Statin Therapy for Patients w/ Cardiovascular Disease
Adult BMI Assessment	Medication Adherence for Diabetes Medications
Osteoporosis Management in Women w/ Fracture	Medication Adherence for Hypertension
Diabetes Care – Eye Exam	Medication Adherence for Cholesterol
Diabetes Care – Kidney Disease Monitoring	Statin Use in Persons with Diabetes

Medication adherence measures are triple weighted in the HEI.

? Questions Payers Should Investigate

- How is my plan and contracts currently performing on the individual Health Equity Index quality measures?
- How would my plan and contracts perform and rank on the Health Equity Index summary score?

Composite Health Equity Index: How Does it Work?

Measure	QM 1	QM 2	QM 3	QM 4	QM 5	QM 6	QM 7	QM 8	QM 9	QM 10	QM 11	QM 12	QM 13	QM 14
Contract Rank	2	3	1	1	3	2	2	1	1	2	3	1	2	1
Index Score	0	-1	+1	+1	-1	0	0	+1	+1	0	-1	+3	0	+3

Contract level scores for each individual measure are ranked from best to worst performance.

- Contracts in the top 3^{rd} (Rank 1): Index score = +1
- Contracts in the middle 3^{rd} (Rank 2): Index score = 0
- Contracts in the bottom 3^{rd} (Rank 3): Index Score = -1


The final composite Health Equity Index is the sum of the index scores divided by the weighted number of measures.

HEI = 0.350

- HEI score for this contract = 0.350
- Reward factor = $0.40 \times 0.350 = 0.14$

HEI range -1.0 to +1.0


MA Plan Performance on Medication Related HEI QMs: Dual/LIS/Disabled vs. Non-Dual/LIS/Disabled Members



- MA members with one or more social risk factor were less likely to be adherent to medications.
- o MA members with one or more social risk factor had similar rates of statin use in persons with diabetes and statin therapy in patients with cardiovascular disease.
- o Fewer members with social risk factors received osteoporosis medications after fracture, but more received treatment for rheumatoid arthritis.

It is also important to understand how your MA plan performs compared to other MA plans






In this example we compare Overall Health Plan to Other MA Plans nationally.

This information can be used to identify which measures the plan is performing worse than comparison MA plans.

Overall MA plan performance could be generated by state or selected geographic regions.

Heatmaps: Regional variation in medication adherence



- Heatmaps at a national, state, or county level can be informative to identify geographic areas with the largest disparities in outcomes
 - o In this example, on average, residents in southern and more rural states are less likely to adhere to their medications than patients in the Midwest and Northeast

Take-Aways

- 1. Start taking action now for the HEI reward factor that begins in 2027
- 2. Leveraging and sharing data is crucial to improving medication use disparities
- 3. Strategic partnerships are critical to redesign the healthcare ecosystem
- 4. Measure Progress